These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 7202473)

  • 21. The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses.
    McAllister RG; Kirsten EB
    Clin Pharmacol Ther; 1982 Apr; 31(4):418-26. PubMed ID: 7060323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of verapamil in man.
    Koike Y; Shimamura K; Shudo I; Saito H
    Res Commun Chem Pathol Pharmacol; 1979 Apr; 24(1):37-47. PubMed ID: 432439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Verapamil kinetics in normal subjects and patients with coronary artery spasm.
    Freedman SB; Richmond DR; Ashley JJ; Kelly DT
    Clin Pharmacol Ther; 1981 Nov; 30(5):644-52. PubMed ID: 7297023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacodynamics of acute intranasal administration of verapamil: comparison with i.v. and oral administration.
    Arnold TH; Tackett RL; Vallner JJ
    Biopharm Drug Dispos; 1985; 6(4):447-54. PubMed ID: 4084670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of steady-state verapamil plasma concentrations in children and adults.
    Wagner JG; Rocchini AP; Vasiliades J
    Clin Pharmacol Ther; 1982 Aug; 32(2):172-81. PubMed ID: 7094504
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of bioavailability for drugs with a high first-pass effect using oral clearance data.
    Somogyi A; Eichelbaum M; Gugler R
    Eur J Clin Pharmacol; 1982; 22(1):85-90. PubMed ID: 7094978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pharmacodynamic and pharmacokinetic differences of the D- and L-isomers of verapamil: implications in the treatment of paroxysmal supraventricular tachycardia.
    Hoon TJ; Bauman JL; Rodvold KA; Gallestegui J; Hariman RJ
    Am Heart J; 1986 Aug; 112(2):396-403. PubMed ID: 3526855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing. Studies with deuterated verapamil.
    Eichelbaum M; Somogyi A
    Eur J Clin Pharmacol; 1984; 26(1):47-53. PubMed ID: 6714292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validation of the hepatic blood flow rate model for verapamil first-pass metabolism.
    Popović J
    Eur J Drug Metab Pharmacokinet; 2007; 32(1):13-9. PubMed ID: 17479539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration.
    Eichelbaum M; Mikus G; Vogelgesang B
    Br J Clin Pharmacol; 1984 Apr; 17(4):453-8. PubMed ID: 6721991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacodynamic profile of verapamil in relation to absolute bioavailability: investigations with a conventional and a controlled-release formulation.
    Harder S; Thürmann P; Siewert M; Blume H; Huber T; Rietbrock N
    J Cardiovasc Pharmacol; 1991 Feb; 17(2):207-12. PubMed ID: 1709224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct determination of hepatic extraction of verapamil in cardiac patients.
    Woodcock BG; Schulz W; Kober G; Rietbrock N
    Clin Pharmacol Ther; 1981 Jul; 30(1):52-6. PubMed ID: 7237898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simultaneous study of the pharmacokinetics of intravenous and oral nicardipine using a stable isotope.
    Guerret M; Cheymol G; Hubert M; Julien-Larose C; Lavene D
    Eur J Clin Pharmacol; 1989; 37(4):381-5. PubMed ID: 2598970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical pharmacokinetics of calcium ion antagonists.
    Eichelbaum M
    Clin Invest Med; 1980; 3(1-2):13-7. PubMed ID: 7471537
    [No Abstract]   [Full Text] [Related]  

  • 35. Chronopharmacology of intravenous and oral modified release verapamil.
    Dilger K; Eckhardt K; Hofmann U; Kucher K; Mikus G; Eichelbaum M
    Br J Clin Pharmacol; 1999 Apr; 47(4):413-9. PubMed ID: 10233206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disposition kinetics and urinary excretion of verapamil and some of its primary metabolites after oral administration in patients with angina pectoris.
    Piotrovskii VK; Rumiantsev DO; Nikolenko SA; Riabokon OS; Metelitsa VI
    Int J Clin Pharmacol Ther Toxicol; 1986 Jan; 24(1):4-11. PubMed ID: 3957489
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Binding processes determine the stereoselective intestinal and hepatic extraction of verapamil in vivo.
    Thörn HA; Sjögren E; Dickinson PA; Lennernäs H
    Mol Pharm; 2012 Nov; 9(11):3034-45. PubMed ID: 23009633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of liver fibrosis on verapamil pharmacokinetics in rats.
    Chen M; Xu D; Hu XL; Wang H
    Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):287-94. PubMed ID: 17973928
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacodynamic comparison of oral and intravenous verapamil in atrial fibrillation.
    Follath F; Fromer M; Meier P; Vozeh S
    Clin Invest Med; 1980; 3(1-2):49-52. PubMed ID: 7009004
    [No Abstract]   [Full Text] [Related]  

  • 40. Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers.
    Popović J; Mitić R; Sabo A; Mikov M; Jakovljević V; Daković-Svajcer K
    Eur J Drug Metab Pharmacokinet; 2006; 31(2):87-96. PubMed ID: 16898076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.